Ultragenyx Pharmaceutical Inc. License Agreements
18 Contracts & Agreements
- Second Amendment to Option and License Agreement, dated December 17, 2021, by and between REGENXBIO, Inc. and Ultragenyx Pharmaceutical Inc (Filed With SEC on February 15, 2022)
- Amendment to the License Agreement, dated as of March 22, 2013, between Ultragenyx Pharmaceutical Inc. and Baylor Research Institute (Filed With SEC on February 12, 2021)
- License Agreement, dated as of September 20, 2012, between Ultragenyx Pharmaceutical Inc. and Baylor Research Institute (Filed With SEC on February 12, 2021)
- First Amendment to Option and License Agreement entered into March 18, 2019 between REGENXBIO Inc. and Ultragenyx Pharmaceutical Inc. (as assignee of Dimension Therapeutics, Inc.) (Filed With SEC on May 7, 2019)
- AMENDMENT NO. 4 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on February 17, 2017)
- AMENDMENT NO. 3 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on November 10, 2015)
- AMENDMENT NO. 2 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on November 10, 2014)
- FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on August 11, 2014)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on December 23, 2013)
- LICENSE AGREEMENT (Filed With SEC on December 23, 2013)
- LICENSE AGREEMENT (Filed With SEC on December 23, 2013)
- AMENDMENT NO. 1 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on November 8, 2013)
- License and Services Agreement (Filed With SEC on November 8, 2013)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 8, 2013)
- LICENSE AGREEMENT (Filed With SEC on November 8, 2013)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 8, 2013)
- AMENDMENT LICENSE AGREEMENT (Filed With SEC on November 8, 2013)
- LICENSE AGREEMENT (Filed With SEC on November 8, 2013)
